A Phase 2/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant for the Preventive Treatment of Migraine

被引：0
|
作者：
Croop, R. [1 ]
Lipton, R. B. [2 ]
Kudrow, D. [3 ]
Stock, D. A. [1 ]
Kamen, L. [1 ]
Conway, C. M. [1 ]
Stock, E. G. [1 ]
Coric, V. [1 ]
Goadsby, P. J. [4 ,5 ]
机构：
[1] Biohaven Pharmaceut, New Haven, CT USA
[2] Albert Einstein Coll Med, Bronx, NY 10467 USA
[3] Calif Med Clin Headache, Santa Monica, CA USA
[4] Kings Coll Hosp London, NIHR Wellcome Trust Kings Clin Res Facil, SLaM Biomed Res Ctr, Kings Coll, London, England
[5] Univ Calif Los Angeles, Neurol, Los Angeles, CA USA
来源：
JOURNAL OF HEADACHE AND PAIN | 2021年 / 22卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
AL054
引用
收藏
页码：19 / 19
页数：1
相关论文
共 50 条
  • [21] A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis
    Wolfgang A. Schmidt
    Bhaskar Dasgupta
    Jennifer Sloane
    Angeliki Giannelou
    Yuqing Xu
    Sebastian H. Unizony
    Sarah L. Mackie
    Miguel A. Gonzalez-Gay
    Robert Spiera
    Kenneth J. Warrington
    Peter M. Villiger
    Michael C. Nivens
    Bolanle Akinlade
    Yong Lin
    Frank Buttgereit
    John H. Stone
    Arthritis Research & Therapy, 25
  • [22] A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, PHASE 3 TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF ANAGLIPTIN IN PATIENTS WITH TYPE 2 DIABETES
    Yang, H. K.
    Lee, S. H.
    Min, K. W.
    Park, S. W.
    Chung, C. H.
    Park, K. S.
    Choi, S. H.
    Song, K. -H.
    Kim, D. -M.
    Lee, M. -K.
    Sung, Y. A.
    Baik, S. H.
    Kim, I. J.
    Cha, B. -S.
    Park, J. H.
    Ahn, Y. B.
    Lee, I. -K.
    Yoo, S. -J.
    Kim, J. T.
    Park, I. B.
    Park, T. S.
    Yoon, K. -H.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2014, 106 : S149 - S150
  • [23] Efficacy of phenazone in the treatment of acute migraine attacks:: a double-blind, placebo-controlled, randomized study
    Göbel, H
    Heinze, A
    Niederberger, U
    Witt, T
    Zumbroich, V
    CEPHALALGIA, 2004, 24 (10) : 888 - 893
  • [24] Efficacy and Safety of Letibotulinumtoxin A in the Treatment of Glabellar Lines: A Randomized, Double-blind, Multicenter, Placebo-Controlled Phase 3 Study
    Mueller, Daniel S.
    Prinz, Valentina
    Adelglass, Jeffrey
    Cox, Sue Ellen
    Gold, Michael H.
    Kaufman-Janette, Joely
    Nestor, Mark S.
    Taylor, Susan
    Frank, Konstantin
    AESTHETIC SURGERY JOURNAL, 2022, 42 (06) : 677 - 688
  • [25] Efficacy, Safety, and Tolerability of Rimegepant 75 mg Orally Dissolving Tablet for the Acute Treatment of Migraine: Results from a Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial, Study 303
    Lipton, Richard B.
    Coric, Vladimir
    Stock, David A.
    Gosden, Ralph
    Forshaw, Micaela
    Croop, Robert
    Conway, Charlie
    CEPHALALGIA, 2019, 39 : 7 - 8
  • [26] Efficacy, Safety, and Tolerability of Rimegepant 75 Mg Orally Dissolving Tablet for the Acute Treatment of Migraine: Results from a Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial, Study 303
    Lipton, R. B.
    Coric, V
    Stock, E. G.
    Stock, D. A.
    Thiry, A. C.
    Conway, C. M.
    Dubowchik, G. M.
    Jensen, C. M.
    Gosden, R.
    Frost, M.
    Gentile, K.
    Morris, B. A.
    Forshaw, M.
    Croop, R.
    HEADACHE, 2019, 59 : 21 - 22
  • [27] Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of erenumab (AMG 334) in migraine prevention: primary results of the STRIVE Trial
    Goadsby, P. J.
    Reuter, U.
    Bonner, J.
    Broessner, G.
    Hallstrom, Y.
    Zhang, F.
    Sapra, S.
    Picard, H.
    Mikol, D.
    Lenz, R.
    EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 117 - 117
  • [28] Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention: Primary Results of the STRIVE Trial
    Goadsby, Peter
    Reuter, Uwe
    Bonner, Jo
    Broessner, Gregor
    Hallstrom, Yngve
    Zhang, Feng
    Sapra, Sandhya
    Picard, Hernan
    Mikol, Daniel
    Lenz, Robert
    NEUROLOGY, 2017, 89 (08) : E104 - E104
  • [29] Safety and efficacy of rimegepant orally disintegrating tablet for the acute treatment of migraine in China and South Korea: a phase 3, double-blind, randomised, placebo-controlled trial
    Yu, Shengyuan
    Kim, Byung-Kun
    Guo, Aihong
    Kim, Man-Ho
    Zhang, Mingjie
    Wang, Zhen
    Liu, Jianguang
    Moon, Heui-Soo
    Tan, Ge
    Yang, Qian
    McGrath, Donnie
    Hanna, Michael
    Stock, David A.
    Gao, Yanfei
    Croop, Robert
    Lu, Zhihong
    LANCET NEUROLOGY, 2023, 22 (06): : 476 - 484
  • [30] Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention: Primary Results of the STRIVE Trial
    Goadsby, P. J.
    Reuter, U.
    Bonner, J.
    Broessner, G.
    Hallstrom, Y.
    Zhang, F.
    Sapra, S.
    Picard, H.
    Mikol, D. D.
    Lenz, R. A.
    HEADACHE, 2017, 57 : 128 - 129
12345